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Senescence is a cellular phenotype present in
health and disease, characterized by a stable
cell-cycle arrest and an inflammatory response
called senescence-associated secretory phenotype
(SASP). The SASP is important in influencing the
behavior of neighboring cells and altering the micro-
environment; yet, this role has been mainly attrib-
uted to soluble factors. Here, we show that both
the soluble factors and small extracellular vesicles
(sEVs) are capable of transmitting paracrine senes-
cence to nearby cells. Analysis of individual cells
internalizing sEVs, using a Cre-reporter system,
show a positive correlation between sEV uptake
and senescence activation. We find an increase in
the number of multivesicular bodies during senes-
cence in vivo. sEV protein characterization by
mass spectrometry (MS) followed by a functional
siRNA screen identify interferon-induced transmem-
brane protein 3 (IFITM3) as being partially respon-
sible for transmitting senescence to normal cells.
We find that sEVs contribute to paracrine senes-
cence.3956 Cell Reports 27, 3956–3971, June 25, 2019 ª 2019 The Author(
This is an open access article under the CC BY license (http://creativeINTRODUCTION
The establishment of cellular senescence is categorized by a
stable cell-cycle arrest and the capacity to modify the microen-
vironment through a particular secretome called SASP (senes-
cence-associated secretory phenotype). The activation of
senescence is a response to different cellular stresses to prevent
the propagation of damaged cells and has been shown to occur
in vitro and in vivo. In fact, an enrichment in the number of senes-
cent cells has been observed in vivo during both biological and
pathological processes such as development, cancer, fibrosis,
and wound healing (He and Sharpless, 2017; Mun˜oz-Espı´n and
Serrano, 2014). The SASP controls its surroundings by reinforc-
ing senescence in an autocrine (cell autonomous) and paracrine
(non-cell autonomous) manner, by recruiting immune cells to
eliminate senescent cells and by inducing a stem cell-like pheno-
type in damaged cells (Mosteiro et al., 2016; Ocampo et al.,
2016). The SASP provides the necessary balance to restore tis-
sue homeostasis when it has been compromised. Paradoxically,
the SASP can also contribute to the enhancement of tissue dam-
age and the induction of inflammation and cancer proliferation.
Overall, the mechanisms behind the pleiotropic activities of the
SASP in different contexts are not well understood (Salama
et al., 2014).
Most studies in vitro and in vivo have attributed the diverse
functions of the SASP to individual protein components suchs).
commons.org/licenses/by/4.0/).
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Figure 1. Small Extracellular Vesicles (sEVs) and Soluble Factors Form Part of the Senescent Secretome andMediate Paracrine Senescence
in Normal HFFF2s
(A) Schematic representation of the proof-of-concept experiments performed to show that sEVs form part of the senescent secretome. HFFF2 human primary
fibroblasts expressing a vector encoding an inducible form of H-RASG12V ER:RAS (iRAS) or an empty vector (iC) were treated with 200 nM 4OHT for 2 days and
allowed to produce conditioned media (CM) for a further 3–5 days. This CM was taken from iC or iRAS HFFF2s and tested for the ability to induce senescence in
HFFF2 as a whole (Figure S1A) or (Figures 1B–1E) processed by serial ultracentrifugation to evaluate the effect of the different fractions: supernatant (SN), large
extracellular vesicles (MVs), or sEVs to induce paracrine senescence in HFFF2s.
(legend continued on next page)
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as interleukin-6 (IL-6) or IL-8 to reinforce autocrine senescence
(Acosta et al., 2008; Kuilman et al., 2008) or transforming growth
factor b (TGF-b) as the main mediator of paracrine senescence
(Acosta et al., 2013; Rapisarda et al., 2017) or to a dynamic
SASP with a switch between TGF-b and IL-6 as predominant
individual components (Hoare et al., 2016). However, it is still
unclear how these diverse SASP components regulate senes-
cence. In fact, inhibition of the SASP by blocking the mammalian
target of rapamycin (mTOR) only partially prevents paracrine
senescence, suggesting that alternative mechanisms may exist
(Herranz et al., 2015; Laberge et al., 2015).
Exosomes are small extracellular vesicles (sEVs) (30–120 nm)
of endocytic origin, whereas microvesicles are formed by the
shedding of the plasma membrane. Exosomes and microve-
sicles are secreted by all cell types and found in most bodily
fluids. Both contain nucleic acids, proteins, and lipids that gener-
ally reflect the status of the parental cell and can influence the
behavior of recipient cells locally and systemically (O’Loghlen,
2018; Tkach and The´ry, 2016). The increasing literature
regarding EVs show that they are disease biomarkers (Melo
et al., 2015), indicators of cancer metastasis (Hoshino et al.,
2015), and therapeutic carriers (Kamerkar et al., 2017). However,
although some studies have found an increase in the number of
EVs released during senescence (Lehmann et al., 2008; Taka-
sugi et al., 2017), very little is known regarding the role that
EVs play as SASPmediators in the senescentmicroenvironment.
Here, we show that both the soluble and sEV fractions transmit
paracrine senescence (called sEV-PS herein). The analysis of in-
dividual cells internalizing sEVs using a reporter system shows a
positive correlation between the uptake of sEVs and paracrine
senescence. We can also observe an increase in multivesicular
body (MVB) formation in a mouse model of oncogene-induced
senescence (OIS) and high CD63 staining in human lung fibrotic
lesions enriched in senescent cells. sEV protein characterization
by mass spectrometry (MS) followed by a functional small inter-
fering RNA (siRNA) screen identify the interferon (IFN)-induced
transmembrane protein 3 (IFITM3) within sEVs as partially
responsible for transmitting senescence to normal cells.
RESULTS
sEVs and Soluble Factors from Senescent Fibroblasts
Mediate Paracrine Senescence
To investigate whether EVs act as intercellular mediators during
senescence, we took advantage of HFFF2 human foreskin
primary fibroblasts expressing an empty vector or oncogenic
H-RASG12V in a 4-hydroxytamoxifen (4OHT)-inducible form
(ER:EV or ER:H-RASG12V). These cells undergo senescence
upon treatment with 200 nM 4OHT (Rapisarda et al., 2017),
without activating the apoptosis pathway, and we have called(B and C) HFFF2 fibroblasts were treated for 72 h with the different fractions of the
different markers of senescence was determined as shown in (B) representativ
different antibodies by IF. The graphs represent the means ± SDs of 2–6 independ
and p16INK4A.
(D and E) HFFF2 cells were treated twice for 72 h with the different fractions of th
performed. (E) Growth curves showing the mean of 3 independent experiments.
See also Figure S1.
3958 Cell Reports 27, 3956–3971, June 25, 2019them iC or iRAS, respectively. The treatment of HFFF2s with
whole conditioned media (CM) from iC and iRAS (mimicking
OIS) confirm previous findings that senescence can be trans-
mitted in a non-cell-autonomous (paracrine) fashion (Acosta
et al., 2013). Recipient HFFF2s present a decrease in cell prolifer-
ation (staining with crystal violet) and an increase in the percent-
age of cells staining positive for senescence-associated-b-galac-
tosidase (SA-b-Gal) (Figure S1A). Next, we dissected the CM
from iC and iRAS HFFF2s and isolated large (MV) and small EV
(sEV) from the same CM. We followed the well-characterized
serial ultracentrifugation protocol (The´ry et al., 2006) filtering the
sEV fraction with a 0.22-mm filter and compared the effect of
the MV and sEV fractions in inducing paracrine senescence in
comparison to the supernatant (SN) fraction (soluble fraction
depleted of MV and sEV) (Figure 1A). Both the SN and sEV
fraction from iRAS cells induced an upregulation of several
markers of senescence in normal HFFF2 compared to iC, as
shown by a decrease in bromodeoxyuridine (BrdU) incorporation,
an increase in p16INK4A protein expression levels, the percentage
of positive cells for phosphorylated-gH2AX (p-gH2AX), and the
accumulation of p53 by immunofluorescence (IF) (Figures 1B
and 1C). AlthoughMVs isolated from iC or iRAS induced a reduc-
tion in the incorporation of BrdU, no othermarkers of senescence
were observed, suggesting that only the SN and sEVs from iRAS
cells transmit paracrine senescence. Next, to determine whether
the cell-cycle arrest observed by the delay in proliferation was
maintained long term, we treated HFFF2 twice for 72 h with the
different fractions, replated the cells, and determined the growth
potential at different days (Figure 1D). As observed in Figure 1E,
only the SN and sEV fractions derived from iRAS cells were able
to induce a delay in proliferation in comparison with the iC. To
confirm sEV-PS induction, we treated HFFF2s with increasing
concentrations of sEVs derived from iRAS compared to the high-
est dose of sEVs from iC and observed a dose-dependent senes-
cent response by quantifying the percentage of cells staining
positive for SA-b-Gal and the levels of p53+ and BrdU+ cells by
IF (Figures S1B and S1C). Furthermore, treatment of HFFF2
with the same number of sEVs also transmits the senescent
phenotype as shown by the decrease in BrdU incorporation
and IL-8 staining by IF (Figure S1D), suggesting that the sEV con-
tent but not particle number is responsible for sEV-PS. To confirm
that sEV-PS was not due to contaminants present in our sEV
preparations, we isolated sEVs using an alternative isolation
technique, size exclusion chromatography (SEC). The absence
of protein contaminants and presence of particles in the sEV frac-
tions were determined (not shown). As can be seen in Figure S1E,
sEV isolated by SEC can also mediate paracrine senescence.
Therefore, both the soluble fraction and sEVs are responsible
for mediating a delay in proliferation and inducing an increase
in the expression levels of diverse biomarkers of senescence.CM (SN, MV, or sEV) from iC or iRAS cells, and the endogenous expression of
e pictures and by (C) quantifying the percentage of cells staining positive for
ent experiments. Scale bars: 100 mm for BrdU and p53 and 30 mm for p-gH2AX
e CM, replated, and counted on different days. (D) Scheme of the experiments
A B
C D
E
F
G
H
Figure 2. Transcriptome Analysis Shows that sEVs Induce a Senescent Signature
(A) Schematic representation of the experimental setting where HFFF2s were treated for 72 h, with sEVs isolated from iRAS cells (mimicking OIS) or HFFF2s
treated with Etop (mimicking DDIS) and sent for RNA sequencing.
(B) Gene Ontology (GO) analysis for genes involved in cellular processes with >2 log2 fold differential expression and p < 0.05 in both OIS- and DDIS-treated
HFFF2s. The pie chart shows a high proportion of genes related to the ‘‘cell-cycle’’ and ‘‘cell proliferation’’ pathways.
(legend continued on next page)
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The sEV Fraction Extracted from iRAS Cells Contains
Exosome-like Particles
Next, we wanted to determine whether the sEV fraction isolated
from iC and iRAS cells contained exosomes. The comparison of
immunoblotting analysis of cells and sEV lysates derived from iC
and iRAS cells showed the presence of different exosome-
related proteins (CD63, TSG101, and ALIX) in our sEV prepara-
tions (Figures S1F and S1G). Furthermore, we confirmed the
absence of proteins related to intracellular compartments, cal-
nexin (endoplasmic reticulum), and COX IV (mitochondria) to
assess the purity of our sEV preparations (Figure S1G). Changes
in the expression levels of annexin V could not be observed be-
tween iC and iRAS cells lysates, while it was detected in sEVs
derived from iRAS cells, as described (Ostrowski et al., 2010;
The´ry et al., 2018) (Figure S1H). We verified the sEV morphology
and size by transmission electron microscopy (TEM) (Figure S1I)
and the sEV population released in iRAS cells by specifically
capturing sEVs onto beads coated with a CD63 antibody, fol-
lowed by a CD81-phycoerythrin (PE)-conjugated antibody. In
fact, at different time points after inducing senescence, an
increase can be seen in CD81 fluorescence intensity and there-
fore a release in sEVs containing simultaneously CD63+/CD81+
(Figure S1J). Previous studies have shown that cells undergoing
senescence release more sEVs (Kavanagh et al., 2017; Leh-
mann et al., 2008; Takasugi et al., 2017). Thus, we quantified
the number and size of sEVs by nanoparticle tracking analysis
(NTA) in iRAS cells and HFFF2s treated with 50 mM etoposide
(Etop) for 48 h, which does not induce apoptosis, followed by
5 days’ incubation with fresh medium (mimicking DNA dam-
age-induced senescence [DDIS]). As shown in Figure S1K, an
increase in sEV release during senescence can be observed
by NTA analysis. We also show an increase in the release of
sEVs during senescence in a variety of human cells and mouse
cells: (1) human breast primary fibroblasts expressing ER:H-
RASG12V (Rapisarda et al., 2017); (2) breast cancer cells,
MCF7, treated with 500 nM of the CDK4/6 inhibitor palbociclib
(Palbo) for 10 days as previously described (Rapisarda et al.,
2017); and (3) ex vivo mouse hepatic stellate cells (mHSCs)
derived from an adult mouse harboring a doxycycline (Dox)-
inducible construct to express shp53 (Krizhanovsky et al.,
2008; Lujambio et al., 2013) (Figure S1L). We did not observe
changes in sEV size distribution with any of the triggers of
senescence (data not shown). Our results show that different
triggers of senescence induce the release of sEVs in a variety
of human cells and mouse cells and that some of these sEVs
present exosome-like features.(C) Kyoto Encyclopedia of Genes andGenomes (KEGG) pathway analysis shows t
isolated from senescent cells (from both OIS and DDIS).
(D) Bioinformatics analysis of SASPmRNA transcripts in HFFF2 treatedwith sEVs
iRAS cells were treated with 5 mM spiroepoxide (SpE; inhibitor of the enzyme neut
represent the reads per kilobase million (RPKM)-log2 fold difference.
(E) Comparison between the paracrine senescence (PS) signature identified by A
(F) ELISA to determine the concentration of IL-6 and active TGF-b present in the
(G and H) HFFF2 treated with sEVs derived from iRAS cells induce an upregulation
level, as shown by qPCR analysis (G) and an increase in the percentage of cells
All data represent means ± SDs of 2–4 experiments.
See also Figure S2.
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HFFF2s
To confirm that sEVs from senescent cells induce paracrine
senescence (sEV-PS), we performed RNA sequencing (RNA-
seq) of HFFF2s treated with sEVs derived from iRAS and from
HFFF2s treatedwith Etop,mimicking OIS andDDIS, respectively
(Figure 2A). Gene Ontology (GO) analysis of genes deregulated
by >2 log2 fold difference expression levels and p < 0.05 in
both OIS- and DDIS-sEV-treated HFFF2s confirmed a shared
‘‘cell cycle’’ and ‘‘cell proliferation’’ signature (Figure 2B), with
the ‘‘p53 signaling pathway’’ being overrepresented (Figure 2C).
Furthermore, HFFF2 cells treated with sEVs derived from both
OIS and DDIS also showed a significant SASP and ‘‘inflamma-
tory response’’ signature (Figures 2D and S2A). We next used
a small molecule inhibitor, spiroepoxide (SpE), which has been
described as blocking the enzyme neutral sphingomyelinase
(N-SMase) and as inhibiting exosome biogenesis and release
(Hannun and Obeid, 2008; Trajkovic et al., 2008). Treatment of
iRAS cells with SpE (5 mM) did not induce cell death. However,
we did observe prevention of the senescent signature by RNA-
seq and a decrease in sEV release by fluorescence-activated
cell sorting (FACS) (Figures 2D and S2B) and NTA (Figure S2C).
Comparison of the paracrine senescent signature previously
described to be mediated by soluble factors (Acosta et al.,
2013) (SN-PS) with the signature provided by sEVs (sEV-PS) in
the RNA-seq data show a significant correlation between both
mediators of senescence (Figure 2E). ELISA analysis of different
SASP components in the SN or within lysed sEVs shows that the
concentration of IL-6, IL-8, or active TGF-b (Figures 2F and S2D)
in sEV lysates from iRAS is similar to or lower than the concentra-
tion observed in the SN from iC samples, which cannot induce
senescence (Figure 1). Similar results were observed analyzing
the CM (data not shown), suggesting that these individual
SASP components are not responsible for sEV-PS.
Validation of the RNA-seq data shows that HFFF2s treated
with iC and iRAS-derived sEVs show an increase in the mRNA
expression levels of cell-cycle regulators CDKN2A, CDKN1A,
components of the SASP, and integrin b3 subunit (ITGB3), which
regulates senescence (Rapisarda et al., 2017) (Figures 2G and
S2E). A comparable response was observed by IF and immuno-
blotting at the protein level (Figures 2H and S2F). Similar results
were obtained in HFFF2s treated with sEVs isolated from
HFFF2s undergoing DDIS (Figure S2G). iRAS HFFF2s express-
ing a vector encoding for 2 previously characterized short hairpin
RNAs (shRNAs) targeting TP53 (shp53) and CDKN2A (shp16)
that prevent the establishment of senescence (Acosta et al.,he ‘‘p53 signaling pathway’’ as representative upon HFFF2 treatment with sEVs
from iRAS and iC cells. The upregulation of SASP transcripts is prevented when
ral sphingomyelinase N-SMase). Data have been normalized to the control and
costa et al. (2013) by soluble factors (SN) with the sEV-PS signature.
SN and sEV lysed fractions.
of cell-cycle inhibitors (CDKN2A,CDKN1A) and SASP (IL-6, IL-8) at the mRNA
staining positive for IL-8 by IF (H). Scale bar, 30 mm.
γγ
γ
A
B
C
D
E F
0.4µm
Figure 3. Inhibition of the Enzyme Neutral Sphingomyelinase, N-SMase, Prevents Paracrine Senescence
(A) Schematic representation of the experimental settings to determine whether inhibition of N-SMase influences paracrine senescence. iRAS cells were treated
with 200 nM 4OHT for 2 days, followed by treatment with different concentrations of Torin-2 (25 and 50 nM) or 2 independent N-SMase inhibitors: GW4869 (1 and
10 mM) and SpE (2 and 5 mM) for 3 days. After the incubationwith the inhibitors, cells were washed and allowed to produce fresh CM for 72 h. Normal HFFF2swere
then incubated with this CM for a further 72 h.
(legend continued on next page)
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2008; Rapisarda et al., 2017) show a reduction in the release of
sEVs during senescence (Figure S2H). We next wanted to
confirm that the sEV-PS response was not due to HFFF2 cells
undergoing genotoxic stress.We isolated sEVs fromHFFF2 cells
treated with Etop for 1 day (pre-senescent) and 6 days (senes-
cent) and treated normal HFFF2s to determine their response.
As shown in Figures S2I and S1J, the 6-day-derived sEVs
induced a reduction in BrdU incorporation and an increase in
p-g-H2AX, while no effect was observed upon treatment with
the 1-day isolated sEVs. These data suggest that sEVs mediate
paracrine senescence independently of the SASP and the induc-
tion of early genotoxic damage.
Inhibition of N-SMase Enzyme Prevents Paracrine
Senescence
Next, we investigated whether inhibition of the N-SMase
enzyme prevents sEV-PS. For this, we treated iRAS cells with
increasing concentrations of 2 independent N-SMase inhibitors:
SpE (2 and 5 mM) and GW4869 (1 and 10 mM). Torin-2 (25 and
50 nM), an mTOR inhibitor that suppresses the SASP (Herranz
et al., 2015; Laberge et al., 2015), was used as a control.
None of the inhibitors or concentrations used induced cellular
toxicity. We then washed the treated cells, added fresh media
for 72 h, and treated normal HFFF2s for an additional 72 h
with the altered CMs (Figures 3A–3C). As shown in Figure 3B,
the highest concentrations of SpE and GW4869 prevented the
cell-cycle arrest mediated by the CM of iRAS, while Torin-2
had no effect (Herranz et al., 2015; Laberge et al., 2015). The
bypass of the arrest mediated by the CM from iRAS cells treated
with SpE correlated with a decrease in the expression levels of
p21CIP (Figure S3A). Furthermore, the CM from both GW4869-
and SpE-treated cells prevented the upregulation of IL-8 and
p-gH2AX mediated by the CM of iRAS cells in normal HFFF2
(Figures 3B, 3C, S3B, and S3C). A similar response was
observed in an additional strain of fibroblasts, IMR-90, by
measuring the levels of expression of p21CIP and p-gH2AX by
IF (Figures S3D and S3E). Next, we used Transwell inserts to
induce a physical separation between the cells and used a
0.4-mm pore membrane to avoid the transfer of larger vesicles.
We plated iC and iRAS with the different treatments in the upper
chamber (UC) and later plated HFFF2 in the lower chamber (LC),
adding fresh CM (Figure 3D). As per our previous data, treat-
ment with GW4869 and SpE prevented paracrine senescence,
which was observed by an increase in cells incorporating
BrdU in the LC and expressing lower levels of p16INK4A (Figures
3E and 3F). These data suggest that the dose-dependent inhibi-
tion of N-SMase using two independent small-molecule inhibi-
tors prevents paracrine senescence.(B) CM-treated HFFF2 fibroblasts were then stained to assess for the percentage o
by IF (means ± SEMs of 3–4 experiments; one-way ANOVA).
(C) Representative pictures for p-gH2AX by IF of HFFF2s treated with the CM fro
(D) Schematic representation of the experimental settings and timings to test the i
of 0.4 mm.
(E and F) The lower chamber was stained to quantify the percentage of cells incor
quantification of BrdU incorporation (E) and p16INK4A (F) are shown. Scale bar, 1
All data show the means ± SEMs of 2–3 independent experiments.
See also Figure S3.
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Senescence In Vivo
We next investigated whether proteins involved in the endosome
pathway were differentially expressed during senescence.
HFFF2 cell lysates extracted from iC and iRAS cells showed no
differences at the endogenous levels of TSG101 or ALIX during
senescence, while a clear increase in CD63 and other markers
of senescence (p16INK4A and p21CIP) were detected (Figures
4A and 4B). Subsequently, to test whether CD63 expression
was increased in vivo, we took advantage of human fibrotic
lung samples previously described to be enriched in senescent
cells (Schafer et al., 2017) and evaluated the expression levels
of CD63 by immunohistochemistry (IHC). We observed a signif-
icant increase in CD63 signal in areas enriched for SA-b-Gal+
cells in comparison with areas with fewer SA-b-Gal+ cells in a va-
riety of human fibrotic lung samples (Figures 4C, 4D, and S4A).
Next, to determine whether changes in the endocytic pathway
occur during senescence in vivo, we took advantage of a mouse
model of OIS. We used a transgenic mouse expressing a condi-
tionalPtf1aCre-driven activatedKras (Ptf1aCre;lsl-KrasG12D) allele,
which develops premalignant intra-epithelial neoplasias (PanIN)
(Hingorani et al., 2003), and presents different markers and
features of senescence (Figure S4B) (Caldwell et al., 2012; Mor-
ton et al., 2010). We subjected the pancreas fromwild-type (WT)
or KrasG12D mice to electron microscopy staining and imaging
and found that KrasG12D-derived PanIN showed an increase in
MVB formation in comparison with WT epithelial ducts (Figures
4E and 4F). We also observed an increase in the number of lyso-
somes, secretory vesicles, and mitochondria per cell in PanINs
when compared to WT epithelial ducts (Figure S4B) (Helman
et al., 2016). Therefore, we observed that the endocytic pathway
is altered during senescence in humans and mice in vivo.
sEVs from iC and iRAS Fibroblasts Are Internalized by
Normal HFFF2s
Next, we investigated whether sEVs from both iC and iRAS
cells were being internalized by HFFF2. For this, we generated
iRAS HFFF2 cells expressing an mCherry-CD63 construct
(iRAS;CD63-ch), which release mCherry+ sEVs (CD63-sEV), and
HFFF2s expressing GFP. First, we co-cultured both GFP+ and
iRAS;CD63-ch+ cells in a 1:1 ratio with 200 nM 4OHT for 2 days,
followed by replenishing with fresh media for 4 days (Figure 5A);
after this, the cells were washed twice with PBS to wash away
all non-internalized EVs. We confirmed the presence of CD63-
sEVtransfer inGFP+HFFF2sbyconfocalmicroscopy (FigureS5A)
and the super-resolution Airyscan microscope (Figure 5B).
Furthermore, 3D rotationof a z stack image (Figure5B, rightpanel)
anda 3Dmodeling video (VideoS1) show internalizedCD63-sEVsf cells expressing markers of senescence: incorporation of BrdU and p-gH2AX
m iRAS with or without SpE or GW4869. Scale bar, 50 mm.
mplication of small EVs using the Transwell system with a membrane pore size
porating BrdU and expressing p16INK4A by IF. Representative pictures and the
00 mm. One-way ANOVA test was performed.
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Figure 4. Increase in CD63 Staining and
Multivesicular Body Formation during
Senescence In Vivo
(A and B) Immunoblot for endogenous expression
of (A) ALIX and TSG101 and (B) CD63. p21CIP and
p16INK4A upregulation are positive controls to
confirm the induction of senescence. b-Actin rep-
resents the loading control.
(C) Immunohistochemistry for SA-b-Gal (blue
staining) and CD63 (brown signal) in a represen-
tative human sample of lung fibrosis. H&E staining
is shown (violet). Pictures at top represent areas
enriched in SA-b-Gal+ cells, and pictures at bot-
tom show areas with low SA-b-Gal+ cells.
(D) Quantification of positive pixels for CD63 per
field, normalized by the H&E staining. The Mann-
Whitney test was performed.
(E) Representative transmission electron micro-
scopy images of multivesicular bodies (MVBs) in
wild-type (WT) and KrasG12D-derived PanIN
(KrasG12D). Scale bar, 500 nm.
(F) Quantification of MVB per cell in WT (n = 28
cells) and PanINs (n = 19 cells).
See also Figure S4.within GFP+ HFFF2s. To avoid confounding effects of the SASP,
wepurifiedCD63-sEVs from iRAS;CD63-ch and iC;CD63-ch cells
and treated normal unlabeled HFFF2 cells (Figure S5B). Overall,
we observed that HFFF2 did internalize CD63-sEV particles.
Cre-loxP Reporter System Shows a Positive Correlation
between sEV Uptake and Induction of Paracrine
Senescence
To further confirm a role for sEV-PS and sEV internalization, we
used the Cre loxP reporter system described by Zomer et al.
(2015, 2016). For this, we generated MCF7 breast cancer cells
expressing Cre recombinase (Cre+ MCF7) and MCF7 expressing
a loxP flanked DsRed construct (reporter MCF7), which when re-
combined allows the expression of a downstreamGFP gene (Fig-
ures 5C andS5C). The percentage of recombinationwas between
1%and 2%, as previously described (Zomer et al., 2015), while no
spontaneous recombination was observed. As previously shown
with HFFF2s, MCF7 incubated with sEVs isolated from Palbo-
treated MCF7 undergoes paracrine senescence. By measuringCell Rethe percentage of GFP+ reporter MCF7
cells (that have taken up Cre-sEV), we
observed a positive correlation between
GFP+ and Sudan Black+ cells (Figures
5D and 5E). In fact, the percentage of
GFP+/Sudan Black+ cells is higher upon
treatment with Cre-sEVs isolated from
Palbo-treated MCF7 (Figure 5E). In addi-
tion, we observed that GFP+ MCF7 cells
were negative for Ki67 when treated with
Cre-sEVs derived fromPalbo-treated cells
(Figure 5F) and that the percentage of
GFP+/Ki67+ MCF7 decreased upon treat-
ment with Palbo-derived Cre-sEVs (Fig-
ure 5G). Upregulation of the mRNA levelsof IL-6, IL-8, and CDKN1A (Figure S5E), in addition to an increase
in cells staining positive for Sudan Black and a decrease in cell
number by DAPI, can be observed in Cre-sEV Palbo-treated re-
porter MCF7 cells (Figure S5F). No differences were detected in
the uptake of reporter MCF7 incubated with DMSO or Palbo-
derived sEVs (data not shown). Next, we sorted by FACS the
GFP+ and DsRed+ MCF7 population treated with DMSO or
Palbo-isolated sEVs and evaluated the differences in the induc-
tion of senescence (Figure 5H). Our data show that the Palbo-
treated sEV GFP+ population presents reduced proliferation and
upregulates several markers of senescence, in contrast to the
DsRed+ cell population (Figures 5I, S5G, and S5H). Our data
show a positive correlation between the uptake of sEVs derived
from Palbo-treated MCF7 cells and the establishment of sEV-PS.
The sEV Protein Content Derived from Control and
Senescent Cells Is Diverse
Based on our previous findings that an equal number of control
and senescent-derived sEVs induce sEV-PS and that sEV-PSports 27, 3956–3971, June 25, 2019 3963
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Figure 5. The Uptake of sEVs Derived from Cells Undergoing Senescence Induces Paracrine Senescence
(A) Schematic representation of HFFF2 fibroblasts used for the co-culture experiments. Co-culture of HFFF2 expressing a GFP plasmid and iRAS HFFF2
fibroblasts expressing a retroviral construct encoding for mCherry-CD63 (iRAS;CD63-ch). Cells were plated in a 1:1 ratio and treated with 4OHT for 48 h, followed
by 3–4 days with fresh media.
(B) Representative images showing the uptake of CD63-cherry+ sEVs (CD63-sEV) in GFP cells acquired with the super-resolution microscope Airyscan. Right, a
3D reconstruction of confocal z stack images showing CD63-sEVs inside GFP cells. Scale bar, 20 mm.
(legend continued on next page)
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is concentration dependent, we hypothesized that the sEV
protein content may differ in senescence. For this, we subjected
isolated sEVs from iRAS and Etop-treated HFFF2 and control
cells to label-free quantitative MS analysis (Figure 6A). GO
analysis of the 1,600 proteins identified show the cellular compo-
nent ‘‘extracellular exosome’’ is overrepresented (Figure 6B). To
identify proteins common to both stimuli inducing senescence,
we selected proteins deregulated in both OIS- and DDIS-sEV
versus control sEV with >2 log2 fold change difference and
adjusted false discovery rate (FDR) <0.01 in both OIS and
DDIS. The Venn diagram analysis shows that 265 proteins are
deregulated in sEVs in both OIS and DDIS (Figure 6C), which
group into GO biological processes related to senescence as
‘‘wound healing’’ and ‘‘cell adhesion’’ (Figure 6D). Volcano plot
analysis comparing individually OIS- and DDIS-sEV protein
content versus their respective controls shows that most pro-
teins identified within sEVs derived from senescent HFFF2 are
upregulated (Figure S6A). We found few previously described
components of the SASP within the sEV proteomics analysis.
A comparative analysis between the soluble factors found in pre-
vious publications (Acosta et al., 2013) and the sEV protein con-
tent show no significant correlation (Figure 6E). Therefore, the
protein content in sEVs derived from cells undergoing DDIS
and OIS is different from control-derived sEV protein content,
although many sEV proteins are common to both senescence
inducers.
To establish which of these proteins common to OIS- and
DDIS-derived sEVs are essential to mediate paracrine senes-
cence, we determined an additional cutoff, as follows: (1) >2
log2 fold change, (2) p < 0.05, and (3) >4 peptide fold change be-
tween control and senescent sEVs. After applying this cutoff, we
selected the top 50 most abundant proteins upregulated in both
DDIS and OIS (Figure 6F; Table S1) and conducted a small-scale
screen using siRNA SMARTpool. We used the whole CM from
iRAS as an indicator to determine overall paracrine senescence
in normal HFFF2 using a scramble (Scr) siRNA or previously
validated siRNA targeting TP53 (sip53) and CDKN2A (sip16)
as a positive control (green bars) (Rapisarda et al., 2017) and
determined BrdU incorporation and p21CIP protein levels by IF
(Figures 6G and S6B). From the primary screen, we selected
the top 4 siRNAs that prevented cell-cycle arrest by BrdU and
analyzed additional markers of senescence by IF—p16INK4A and
p-gH2AX (Figure S6C). The IFN signaling pathway has been
recently described as regulating senescence (Yu et al., 2015),
and within the siRNA validated from the screen, we found the(C) MCF7 breast cancer cells expressing a Cre recombinase construct (Cre+ MCF
senescence. sEVs were purified from Cre+ MCF7 cells (Cre-sEV) and used to tr
expressing DsRed to eGFP upon sEV internalization (reporter MCF7).
(D) Representative pictures showing sEV uptake (GFP+ cells) in reporter MCF7s t
cells are also Sudan Black+.
(E) Quantification of the percentage of GFP+ reporter MCF7 treated with sEVs pr
(F) Pictures display sEV uptake (GFP+) in reporter MCF7 cells incubated with Cre-
with Cre-sEV from DMSO cells are also positive for Ki67, while GFP+ cells incub
(G) Quantification of the percentage of GFP+/Ki67+ reporter MCF7 treated with s
(D and F) Scale bar, 100 mm.
(H and I) GFP+ and DsRed+ MCF7 treated with sEVs from both DMSO and Palbo
curve showing the GFP+ and DsRed+ MCF7 populations.
See also Figure S5.IFN-inducible transmembrane protein 3 (IFITM3) (Figure 6G,
red bars).
IFITM3 within sEV Partially Mediates sEV-PS
Our previous data show that IFITM3 (1) is important for CM-
mediated paracrine senescence (Figures 6G, S6B, and S6C),
(2) has not been previously found to be a soluble factor (SN) in
senescence (Figure 6E) (Acosta et al., 2013), and (3) is highly ex-
pressed in sEVs derived from cells undergoing OIS and DDIS
(Figure S6A). To investigate whether the IFN pathway plays a
role in sEV-PS, we analyzed the expression levels of RNA tran-
scripts deregulated in HFFF2 treated with sEVs derived from
OIS and DDIS cells (Figure 2). We found an increase in several
IFITM and the related IFN-induced protein with tetratricopeptide
repeats (IFIT) transcripts upon sEV incubation, but not when
treated with N-SMase (Figures 7A, 7B, and S7A).
We next determined whether the increase in IFITM3 observed
in the MS analysis was due to an increase in the endogenous
expression levels of IFITM3 during senescence. To our surprise,
the endogenous cellular levels of IFITM3 did not change during
senescence in iRAS cells (Figures 7C and S7B), although we
were able to detect an increase in IFITM3 in sEVs (Figure 7D).
By capturing IFITM3+ sEVs onto beads and detecting CD81 by
FACS, we confirmed that iRAS cells released more IFITM3+/
CD81+ sEV particles than the iC cells (Figure 7E). To determine
whether IFITM3+ sEVs belong to the same complex as CD63+
sEVs, we performed the OptiPrep density gradient and
confirmed that they both float at the same density (Figure S7C),
suggesting that sEVs containing IFITM3 are also positive for
CD81 and CD63.
To determine the implication of IFITM3 in sEV-PS, wemanipu-
lated the levels of IFITM3 in donor cells, isolated sEV from these
cells, and measured their ability to induce sEV-PS. We depleted
IFITM3 from iRAS cells using siIFITM3, confirming a reduction in
theexpression levels of IFITM3 in thedonor cells and their derived
sEVs (Figures 7C, 7F, and S7B). The treatment of HFFF2 with an
equal number of sEVs derived from iRAS + siIFITM3 prevented
the upregulation of p16INK4A and IL-8 mediated by sEVs from
iRAS cells (Figure 7G). A similar response was observed using
stable HFFF2 infected with a previously validated shRNA target-
ing IFITM3 (Huang et al., 2011) (Figures S7D and S7E). However,
therewas nodifference in the number of sEVs released from iRAS
cells with or without both siIFITM3 and shIFITM3 (Figure S7F),
confirming that the depletion of IFITM3 did not alter sEV particle
secretion. Next, we generated HFFF2s expressing a lentiviral7) were treated with DMSO or 500 nM palbociclib (Palbo) for 10 days to induce
eat MCF7 cells expressing a fluorescent reporter gene, which switches from
reated with sEVs isolated from Cre+ MCF7 treated with DMSO or Palbo. GFP+
esenting with Sudan Black staining.
sEVs from DMSO- or Palbo-treated cells. Arrows show that GFP+ cells treated
ated with Cre-sEV from Palbo-treated cells are negative for Ki67.
EVs purified from DMSO- or Palbo-treated Cre+ MCF7.
cells were sorted by FACS. (H) Scheme of the experimental settings. (I) Growth
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Figure 6. MS Proteomic Analysis Reveals a Specific Cargo in sEVs Derived from Senescent Cells
(A) Scheme showing themass spectrometry (MS) approach. sEVs were isolated from HFFF2 undergoing either OIS or DDIS from 2 independent experiments and
were sent for label-free MS analysis.
(B) DAVID GO analysis for the 1,600 proteins detected by the MS group into the ‘‘extracellular exosome’’ pathway. FDR, false discovery rate.
(C) Venn diagram for proteins with >2 log2 differential expression and <0.01 FDR in sEVs released during OIS and DDIS compared to controls shows 265 common
proteins that are deregulated during senescence.
(D) GO analysis groups the 265 proteins into biological processes related to senescence-like ‘‘wound healing’’ and ‘‘response to wound healing.’’
(E) Comparison of the components of the soluble factors (SN) reported by Acosta et al. (2013) and the protein composition found within sEVs during senescence.
IFITM3 is an example of a protein found specifically in the sEV fraction during senescence.
(legend continued on next page)
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vector encoding an myc-tagged IFITM3 construct, in which we
were able to confirm the ectopic expression of IFITM3 in both
cell lysates and their respective sEVs (Figures 7H and S7G). In
accordance with our previous data that the endogenous levels
of IFITM3 do not change during senescence (Figure 7C), we did
not observe any changes in the expression levels of a number
of markers of senescence by immunoblot or qPCR (data not
shown) upon the ectopic expression of IFITM3 in normal HFFF2s
(Figure S7G) or changes in the release of a number of sEVs (Fig-
ure S7H). However, we could still observe a slight upregulation of
p16INK4A and an increase in p-gH2AX when we treated HFFF2
with sEVs isolated from IFITM3-expressing cells by IF, although
these were not as prominent as the upregulation mediated by
iRAS-derived sEVs (Figure 7I). Therefore, IFITM3 is not involved
in regulating senescence, although changes in its expression
levels within sEVs partially influence sEV-PS.
IFITM3 Is Highly Expressed in sEVs Derived from Elderly
Human Donors
To determine whether IFITM3 could be involved in aging, we iso-
lated sEVs from human plasma derived from 4 young (33 years
old) and 10 elderly (80 years old) donors and determined the
expression levels of IFITM3 protein by immunoblotting. The
expression levels of IFITM3 were increased in 6 of 10 elderly
human donors, while there was very little change in the expres-
sion levels of the sEVs derived from young donors (Figures 7J,
7K, and S7I). Furthermore, the elderly human donors released
more sEVs than did their younger counterparts (Figure S7J).
DISCUSSION
Intercellular communication is an important mechanism by
which cells interact with one another. It can be mediated in the
form of soluble factors or extracellular vesicles (Kuilman and
Peeper, 2009; O’Loghlen, 2018; Tkach and The´ry, 2016). Howev-
er, although recent studies have highlighted the importance of
EVs for cellular homeostasis in the context of senescence (Taka-
hashi et al., 2017), a role for EVs has been neglected, in spite of
some studies having previously found the ‘‘extracellular vesicle
pathway’’ overrepresented by GO analysis of differentially ex-
pressed genes during senescence (Hoare et al., 2016; Lujambio
et al., 2013).
Non-cell autonomous (paracrine) senescence via the SASP
has been previously described as an important mechanism
during senescence (Acosta et al., 2013; Dou et al., 2017; Hoare
et al., 2016; Nelson et al., 2012), although these studies do not
discern between the effect of soluble factors and EVs. Here,
we provide evidence that both the SN and sEVs are respon-
sible for mediating paracrine senescence (SN-PS and sEV-PS,
respectively). In fact, a transcriptome analysis comparing SN-(F) Schematic diagram showing the strategy used for the performance of the siRN
out and replenished with fresh media for 72 h.
(G) Screen using SMARTpool siRNA targeting the 50 most upregulated protein
senescence. Data show BrdU staining by IF for HFFF2s treated with different CM.
were used as negative and positive controls (green bars). siIFITM3 is highlighted
Data represent the means ± SEMs of 3 independent experiments.
See also Figure S6.PS (Acosta et al., 2013) and sEV-PS shows a significant senes-
cent signature. Furthermore, a broad MS analysis of the
published protein composition of SN (Acosta et al., 2013) and
the present article’s sEV proteomics shows little correlation be-
tween both fractions, suggesting that although the downstream
signaling is similar, the triggers inducing senescence are diverse.
However, a more comprehensive and sensitive methodology
would be needed to confirm this. The use of a Cre loxP reporter
system to determine EV internalization shows a positive correla-
tion between sEV uptake and paracrine senescence activation.
Recently, many studies have found a cellular response that is
characteristic of infectious agents during senescence in the
absence of pathogens. For example, it has been shown that
the SASP is regulated by the inflammasome via IL-1a signaling
(Acosta et al., 2013) and by the cGAS-STING (cyclic guanosine
monophosphate [GMP]-AMP synthase linked to the stimulator
of IFN genes) pathway (Dou et al., 2017; Gl€uck et al., 2017;
Yang et al., 2017). Both pathways are induced during senes-
cence in the absence of pathogens or double-stranded DNA.
MS analysis of sEVs derived from OIS and DDIS show that
IFITM3, which is implicated in the IFN signaling pathway, is accu-
mulated in sEVs derived from both OIS and DDIS and is not
detectable in the soluble fraction of the SASP (Acosta et al.,
2013). IFITM3 endogenous expression levels are unchanged in
donor cells during senescence but accumulate in sEVs derived
from iRAS, which may suggest that IFITM3 could be selectively
packaged into sEVs during OIS. We find that IFITM3 within
sEVs is partially responsible for sEV-PS, as depletion of IFITM3
from sEVs using independent RNAi partially prevents sEV-PS.
Conversely, the generation of a stable HFFF2 cell line ectopically
expressing IFITM3 does not induce senescence in the donor
cells, while sEVs derived from these cells are capable of inducing
a DNA damage response and upregulation of p16INK4A. In fact,
other investigators have found that IFN signaling can be
mediated via EVs in neural stem cells (Cossetti et al., 2014; Li
et al., 2013) and that DNA from senescent cells can be secreted
via EVs (Takahashi et al., 2017). The relevance of individual
components within EVs has also been described in different
biological contexts such as cancer. EVs contain particular pro-
tein components, such as major histocompatibility complex
(MHC) molecules, integrins, or the receptor kinase MET, that
allow both immunosuppression and evasion of immune surveil-
lance (O’Loghlen, 2018). However, that additional components
of the senescent sEV (DNA, RNA, or lipids) could play a role in
mediating sEV-PS cannot be dismissed.
Here, we show that PanINs, which are enriched in senescent
cells, present a higher number of MVBs per cell than their WT
counterparts. Furthermore, the increase in CD63 staining in re-
gions enriched in senescent cells in human lung fibrotic tissues
suggests that a positive correlation between CD63 endogenousA screen. Briefly, after transfection with the siRNA, the whole CM was washed
s in both OIS and DDIS with >4 peptide fold difference between control and
A scramble siRNA (Scr) and siRNA targeting TP53 (sip53) and CDKN2A (sip16)
in red.
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Figure 7. IFITM3 within sEVs Is Partially Responsible for Inducing Paracrine Senescence
(A and B) HFFF2s incubated with sEVs derived from iRAS cells show an increase in transcripts related to the interferon (IFN) pathway (A)—in particular, IFITM
(in red) and IFIT mRNAs, which are downregulated when treated with SpE.
(B) IFITM transcripts are specifically shown.
Data in (A) and (B) have been normalized to the control and represent the mean of 3 independent experiments (RPKM-log2 fold difference).
(C and D) Immunoblotting analysis for IFITM3 in (C) cell lysates derived from iRAS HFFF2s transfected with Src or siIFITM3 and in (D) sEV (33 109 particles) from
iC and iRAS cells. b-Actin and ALIX are used as loading controls.
(legend continued on next page)
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expression andOIS occurs in vivo. It is interesting that elderly hu-
man donors release more sEVs and that the sEVs found in
plasma show higher protein levels of IFITM3 in 60%of the elderly
donors. Although it may be tempting to speculate that IFITM3
within sEVs could be involved in aging, a larger cohort of young
and elderly patients would be needed.
We show here that sEVs are responsible for mediating para-
crine senescence and speculate that they could be involved in
inducing bystander senescence during therapy-induced senes-
cence (Demaria et al., 2017) or aging (Acosta et al., 2013; Nelson
et al., 2012). In fact, when compared to soluble factors, sEVs
have different biophysical and biochemical properties as they
have a longer lifespan than do soluble factors and they are
more resistant to protease degradation (O’Loghlen, 2018). The
idea that blocking sEV secretion could be a potential therapeutic
approach to alleviate senescence ‘‘spreading’’ during chemo-
therapy-induced senescence or in aging tissues presents itself
as a very attractive tool for the future.
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ELISA IL-6 Mab Tag GmbH h-IL6-EIA-1
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b-Galactosidase Staining kit Cell Signaling #9860LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ana
O’Loghlen (a.ologhlen@qmul.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture
HFFF2 human foreskin primary fibroblasts (male) were obtained from the Culture Collections (Public Health England, UK). IMR-90
(female), MCF7 (female) and HEK293T (female) were bought from ATCC. Breast fibroblasts (BF) were isolated from a female breast
mastectomy and have been described elsewhere (Rapisarda et al., 2017). All cells were grown in high glucose Dulbecco’s modified
Eagle’s medium with 10% fetal bovine serum and 1% antibiotic-antimycotic solution. Mouse hepatic stellate cells were a kind gift
from Scott Lowe and were grown in 1 mg/ml of Doxycycline.Cell Reports 27, 3956–3971.e1–e6, June 25, 2019 e2
Mice samples
6week-oldPtf1aCre;lsl-KrasG12Dmicewere injected subcutaneouslywith two doses, twodays apart, of 400mg tamoxifen per 20 gmice
(Tamoxifen (Sigma) stock 20 mg/ml in corn oil) to obtain acinar cell-specific activation of KrasG12D. Mice were euthanized 5 months
following treatment. All mice experiments were done with approval from the Hebrew University Animal Care and Use Committee.
Human EV plasma samples
Young donors were all male with an age range between 29-36 years old, while old donors were a mix between male and female and
age range between 70-92. None of the donors presented underlying diseases. The study was approved by the London - City & East
Committee (10/H0704/73) and all donors gave informed written consent to participate.
Human lung samples
Human tissues were received from the Papworth Hospital Research Tissue Bank (REC 08/H0304/56+5).
METHOD DETAILS
Soluble fraction, MV and sEV isolation
All cells were maintained in sEV-depleted FBS. FBS was depleted of sEV by overnight (ON) ultracentrifugation at 100,000 g at 4C
(Sorvall 100SEUltracentrifuge). The supernatant was removed and stored in 50mL falcons at20Cuntil required. CMwas collected
after 72h incubation with cells, unless specified otherwise.
To isolate the different EV fractions, the protocol of differential ultracentrifugation (The´ry et al., 2006, 2018) was modified and
adapted. Whole CM was centrifuged at low speed (2,000 g for 20min) to eliminate dead cells and cellular debris prior to use. MV
were collected after the 10,000 g centrifugation step for 1h, washed with PBS and spun down again at 10,000 g for 1h. The super-
natant was then filtered through a 0.22mm filter prior to the 100,000 g centrifugation step and also after in some cases (for the Cre-
LoxP experiments). The supernatant was collected after a 1h and 20min 100,000 g centrifugation step and concentrated using a 10K
column (Amicon Ultra-0.5 Filter) at 14,000 g for 10min obtaining a concentration factor 10X. The final 100,000 g pellet was washed
once in 15ml of PBS and resuspended in 100 mL of 10% FBS-depleted media for the functional cell culture experiments. For the
MCF7 functional experiments the pellet was resuspended in 0.5% FBS-depleted media. Alternatively, for Western Blot analysis,
sEV pellet was re-suspended in protein lysis buffer. A Sorvall 100SE Ultra Centrifuge, with a Beckmann Fixed Angle T865 rotor
was used for all sEV isolations. The k-factor of the rotor is 2,08. We have submitted all relevant data of our experiments to the
EV-TRACK knowledgebase (EV-TRACK ID: EV190024).
Density gradient sEV isolation
sEV isolated by serial ultracentrifugation were re-suspended in 1.5 mL of suspension buffer (0.25M sucrose, 10mM Tris pH 8.0 and
1mM EDTA (pH 7.4) (Sigma-Aldrich, USA). Next, sEV were mixed 1:1 with 60% stock solution of iodixanol/Optiprep (Sigma-Aldrich,
USA). Then, 1.4ml 40% iodixanol, 1.3ml 20% iodixanol and 1.2ml 10% iodixanol were successively layered on top of the sEV sus-
pension and tubes were centrifuged at 100,000 g ON, stopping without break. After centrifugation, ten fractions of 700ml were
collected from the top of the tube. Fractions werewashedwith 15ml PBS at 100,000 g for 1h 20min. The fractions were re-suspended
in 50 mL of lysis buffer.
Size exclusion sEV isolation
CMwas centrifuged at 350 g for 15min at 4C to pellet cells. The supernatant was centrifuged at 2,000 g for 20min at 4C and filtered
with a 0.22mm filter. Size exclusion chromatography (SEC) using qEV columns (Izon Science, USA) was used to the isolate sEV.
Twelve eluted fractions were collected in sequential fractions of 1ml according to the manufacturer’s instructions. The particle
and protein concentration of each fraction was thenmeasured by NTA andMicroBCA. The fractions enriched in particles and lacking
protein contaminants were pooled, centrifuged at 100,000 g for 1h 20 min and used for functional assays.
Treatment of cells with CM or isolated sEV
HFFF2 fibroblasts were plated in a 100mm dish at 1x106 cells. After 24h, iC and iRAS cells were treated with 200nM 4OHT for 48h in
10% media, washed, incubated with 0.5% media and allowed to produce new CM for 72h. The sEV obtained from these cells were
used to treat 10-12 wells of a 96-well plate.
Young HFFF2 were treated with the CM from several experiments previously centrifuged at low speed to discard dead cells and
supplemented with FBS to reach 10% in the final volume. HFFF2 treated with isolated sEV were also supplemented with media con-
taining 10% FBS, while in the experiments performed with MCF7, the cells were incubated with isolated exosomes resuspended in
0.5% FBS media.
CM with siRNA and inhibitors functional experiments
24h after plating HFFF2 in 96-well plates, senescence was induced by adding 200nM 4OHT. 48h after the cells were washed and
supplemented with 0.5%FBS and the indicated inhibitors for 2-3 days, after which plates were washed again to remove the inhibitorse3 Cell Reports 27, 3956–3971.e1–e6, June 25, 2019
from the media and supplemented with fresh media (0.5% FBS) for further 72h. For the experiments with the siRNA, reverse trans-
fection with 50nM siRNA was performed and the media replenished (10% FBS) with 4OHT after 2 days and left for an additional 48h.
After, the cells were washed to remove all siRNA from the media and incubated with 0.5% FBS fresh media for an additional 72h.
Nanoparticle tracking analysis (NTA)
Prior to the NTA analysis, the NanoSight LM10 equipped with a 405nm laser (Malvern Instruments) was calibrated using Silica
Microspheres beads (Polyscience). Samples to be measured were then diluted in PBS in order to obtain a particle number between
108-109 particles. At least three repeated-measurements of 60 s were taken per each individual sample and themean value was used
to determine particle number. Static mode (without flow) was used for each analysis. The movement of each particle in the field of
view was measured to generate the average displacement of each particle per unit time which was calculated using the NTA 3.0
software.
Affinity-based capture of exosomes on beads
For exosome characterization by flow cytometry, aldehyde/sulfate latex beads (Thermo Fisher) were coated with anti-CD63 or anti-
IFITM3 antibody and incubated with the different CM overnight at 4C in a rotation wheel. After extensive washing, anti-CD81-PE
conjugated antibody was added for further 40min at RT, washed with PBS and acquired using NovoCyte Flow Cytometer (Acea,
Biosciences) with a 488nm laser. Gates were set using the NovoExpress Software (Acea, Bio) to analyze single bead fluorescence.
Isotype-matching coated beads were used as a negative control in all experiments.
FACS sorting of GFP+ and DsRed+ MCF7 cells
Reporter MCF7 incubated with sEV isolated from DMSO and Palbo treated Cre+ MCF7, were washed twice with PBS, analyzed and
sorted into two populations (GFP+ and DsRed+) using FACS Aria Ill Cell Sorter (BD Biosciences). Cell debris was discriminated by the
cell forward scatter (FSC) and side scatter (SSC) properties. FACS data sorter was generated using BD FACDIVA SoftwareTM v.8.0.1
(BD Biosciences).
Transmission Electron Microscopy
Mouse pancreatic tissue
Mice were perfused with PBS followed by using fixative solution (2% PFA / 2.5% glutaraldehyde / 0.1M cacodylate buffer). Small
tissue sections were dissected and placed under rotation in fixative solution for 2h at RT, followed by ON rotation at 4C. After
2 days, the tissue was transferred to 0.1M cacodylate buffer, pH 7.4. After fixation, samples were rinsed several times with 0.1 M
cacodylate buffer and post-fixed in 1% (v/v) osmium tetroxide in 0.1 M cacodylate buffer (pH 7.4) for 1.5h at 4C. Samples were
then en-bloc stainedwith 1% (w/v) aqueous uranyl acetate for 1h at RT, thoroughly washed and dehydrated through a graded ethanol
series before infiltration with epoxy resin (TAAB). Finally, tissue samples were embedded on flat molds and polymerized at 70C for
24h. Ultrathin sections (70-90nm) were cut using a Leica UC7 ultramicrotome mounted on 150 mesh copper grids and contrasted
using Uranyless (TAAB) and 3% Reynolds Lead citrate (TAAB). Sections were examined at 120kV on a JEOL JEM-1400Plus TEM
fitted with a Ruby digital camera (2k x 2k).
Isolated sEV
2.5 mL of sEV resupended in PBSwere placed on Formvar-coated grids and allowed to settle for 3-5min, without being allowed to dry.
sEV were then fixed with 2% glutaraldehyde for 5min and washed three times with distilled de-ionised water. After washing, the grids
were stained for 20min with 3% uranyl acetate: 2% methyl cellulose (1:9). Imaging of sEV was carried out using a JEOL JEM-
1400Plus, operated at 120kV, fitted with a Ruby camera (2k x 2k).
b-Galactosidase staining
Cells were washed with PBS and fixed with 0.05% (w/v) glutaraldehyde (in PBS) for 15mins at RT. Cells were washed a second time
with PBS and incubated with 5-bromo-4-chloro-3-indolyl-beta-D-galacto-pyranoside (X-gal) solution for 1h at 37C. Cells were
imaged after 12-24h using a light microscope (Nikon) at 20Xmagnification and single representative images of each well were taken.
IF b-Galactosidase was performed according to the manufacturer’s instructions using the following commercial kit (Sigma-Aldrich,
#F2756). Briefly, 33 mM of the b-gal substrate C12FDG (Fluorescein di-B-D-galactopyranose) (F2756 Sigma-Aldrich) was added to
the cells for 8h at 37C, After, the cells were washed with PBS and fixed with 4% PFA.
IF staining
Cells grown in 96-well plates were washed with PBS and fixed in 4% paraformaldehyde for 15min at RT. Cells were then washed in
PBS twice before been permeabilized and blocked for 40min with 0.2% Triton X-100 together with 1%BSA and 0.2% gelatin fish
(Sigma). For IF staining, cells were incubated ON with the primary antibody and in the case of BrdU cell were treated with 0.5U/ml
DNaseI and 3mM MgCl2. Cells were then washed in PBS and incubated 1h with secondary antibody, DAPI and Cell Mask Deep
Red (Invitrogen). For confocal images, cells were mounted onto slides using Vectashield Mounting Medium (Vector Laboratories).
Signals were visualized using a Zeiss LSM 880 (Zeiss, Berlin, Germany) provided with Airyscan for super-resolution acquisition.Cell Reports 27, 3956–3971.e1–e6, June 25, 2019 e4
RNA extraction, cDNA synthesis and qPCR
Cells were washed with PBS and lysed directly into the culture dish using TRIzol Reagent (Thermo Fisher). cDNA synthesis was per-
formed using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher). qPCR reactions were performed using SYBR
Green PCRMaster Mix (Applied Biosystems,) on a 7500 Fast System RealTime PCR cycler (Applied Biosystems). Primer sequences
are listed in Table S2.
ELISA
The SN sample was diluted 1:2 prior to the analysis and sEV - isolated by ultracentrifugation - were suspended in 100ml of lysis buffer
to determinate the concentration of TGF-b1, IL-6 and IL-8. Regarding TGF-b1, it was first activated in the samples. All samples were
incubated with 1N HCl for 10min at RT. Then, the acidified samples were neutralized with 1.2 N NaOH/0.5 M HEPES. TGF-b1 was
detected using the quantitative sandwich human TGF-b1 immunoassay (DB100B, R&D systems) and human IL-6 and IL-8 immuno-
assays (h-IL6-EIA-1 and h-IL8-EIA-5 respectively, Mab Tag GmbH). Samples were measured at 540nm using Synergy HT Multi-
Mode Microplate Reader.
Stable gene expression
Stable retroviral and lentiviral expression was performed as in previous studies (Acosta et al., 2008; Rapisarda et al., 2017).
Protein analysis by immunoblotting
sEV and cultured cells were lysed using the following lysis buffer [(Tris-HCl 20 mM pH 7.6; DTT 1 mM; EDTA 1 mM; PMSF 1 mM;
benzamidine 1 mM; sodium molybdate 2 mM; b- sodium glycerophosphate 2 mM; sodium orthovanadate 0.2 mM; KCl 120 mM;
1 mg/ml (each) leupeptin, pepstatin A and antipain; NonidetTM P-40 0.5% (v/v); Triton X-100 0,1% (v/v)], and quantified using a Micro
BCA Protein Assay Kit (Thermo Fisher Scientific) or cell lysates were prepared with Lysis Buffer 6 (R&D Systems), supplemented with
protease inhibitor cocktail (Thermo Fisher Scientific), and protein content was determined using the Advanced Protein Assay
Reagent (Sigma-Aldrich). Lysates were diluted with 4X Laemmli Sample Buffer (Bio-Rad, UK) and equal quantities of total protein
were separated in SDS-PAGE gels, transferred to a PVDF 0.45 mm pore size membrane (Millipore, UK) and probed with different an-
tibodies. Protein bands were detected using a SuperSignal West Pico PLUS Chemiluminescent Substrate (Thermo Fisher Scientific)
and the ChemiDoc XRS+ System (Bio-Rad). Sequential detection of different proteins was performed following HRP inactivation with
30% H2O2 (Sigma-Aldrich) for 30 minutes at 37
C up to five times, or without inactivation where appropriate.
Immunohistochemistry of human lung samples
SA-b-Gal staining was performed in whole tissue, using the Senescence b-Galactosidase Staining kit (Cell Signaling #9860),
following the manufacturer instructions. Briefly, whole tissue was fixed at RT for 45min with a 2% formaldehyde and 0.2% glutaral-
dehyde, washed and incubated ON at 37C with the staining solution containing X-gal in N-N-dimethylformamide (pH 6.0). Tissues
were subsequently dehydrated and embedded in paraffin and sectioned. For the immunohistochemistry, 5mmparaffin sections were
deparaffinized and re-hydrated, and slideswere incubatedwith anti-CD63 (Cell Signaling #55051S). The immunohistological reaction
was developed using 3,3-diaminobenzidine tetrahydrochloride (DAB), and nuclei counterstained with hematoxylin. Positive signal for
SA-b-Gal and CD63 was quantified with ImageJ.
RNA sequencing
For RNA-seq, total RNA was extracted using TRIzol Reagent. First strand cDNA synthesis was performed with SuperScript III First-
Strand Synthesis System. After purification using SPRI beads, the double stranded cDNA was ligated to in-house designed adapters
(based on TruSeq Indexed adapters (Illumina)) using NEBNext Ultra II (NEB) followed by 15 cycles of amplification and library purifi-
cation. Sequencingwas performed on an IlluminaNextSeq500, HighOutput runwith 75bp paired-end at theGenomicsCentre (QMUL).
MS proteomics
LC-MS/MSwas done by coupling a nanoLC-Ultra 1D+ system (Eksigent) to an Impactmass spectrometer (Bruker) via aCaptivespray
source (Bruker) supplemented with a nanoBooster operated at 0.2 bar/min with isopropanol as dopant. Peptides were loaded into a
trap column (NS-MP-10 BioSphere C18 5 mm, 20mm length, NanoSeparations) for 10min at a flow rate of 2.5 ml/min in 0.1%FA. Then
peptides were transferred to an analytical column (ReproSil Pur C18-AQ 2.4 mm, 500 mm length and 0.075 mm ID, Dr. Maisch) and
separated using a 100 min effective curved gradient (buffer A: 4% ACN, 0.1% FA; buffer B: 100% ACN, 0.1% FA) at a flow rate of
250 nL/min. The gradient used was: 0-2min 2% B, 2-102 min 33% B, 102-112 min 98% B, 112-120 min 2% B. The peptides
were electrosprayed (1.35 kV) into the mass spectrometer with a heated capillary temperature of 180C. The mass spectrometer
was operated in a data-dependent mode (130-1600 m/z), with an automatic switch between MS and MS/MS scans using a top
20 method (threshold signalR 500 counts, zR 2 and m/zR 350). An active exclusion of 30 s was used. The precursor intensities
were re-evaluated in the MS scan (n) regarding their values in the previous MS scan (n-1). Any m/z intensity exceeding 5 times the
measured value in the precedingMS scanwas reconsidered forMS/MS. Peptideswere isolated using a 2 Thwindow and fragmented
using collision induced dissociation (CID) with a collision energy of 23-56 eV as function of the m/z value.e5 Cell Reports 27, 3956–3971.e1–e6, June 25, 2019
Human donors sEV isolation
10ml of blood was collected in EDTA vacutainer tubes (Nucare, VS367525). Plasma was obtained by centrifuging the tubes for 5min
at RT at 1500 rpm. sEVwere isolated from 2ml of plasma and centrifuged at 4,000 g for 10min at 4C. Platelet-free plasmawas filtered
(0.22mm) and ultracentrifugated at 100,000 g for 1h 20min. After, the pellet waswashed two timeswith PBS at 100,000 g for 1h 20min.
None of the donors presented any underling disease.
QUANTIFICATION AND STATISTICAL ANALYSIS
qPCR gene expression
Ct valueswere generated using the 7500 software version 2.0.6 (Applied Biosystems). Relative gene expression was calculated using
theDDCtmethod and normalized to a housekeeping gene, RPS14. The relativemRNA expression level changeswere expressed as a
fold change relative to the control or the senescent sample.
IF analysis
Immunofluorescence images were acquired using IN Cell 2200 automatedmicroscope (GE) and the IN Cell 2200 Developer software
version 1.8 (GE) as previously (Acosta et al., 2008; Rapisarda et al., 2017). Regarding the confocal images, rotating 3D reconstruction
of confocal Z stack images were obtained using Zeiss Zen 2011 software.
MS proteomics analysis
Raw files were processed with MaxQuant (v 1.5.3.30) using the standard settings against a human protein database (UniProtKB/
Swiss-Prot, August 2016, 20,195 sequences) supplemented with contaminants. Label-free quantification was done with match
between runs (match window of 0.7 min and alignment window of 20 min). Carbamidomethylation of cysteines was set as a fixed
modification whereas oxidation of methionines and protein N-term acetylation as variable modifications. Minimal peptide length
was set to 7 amino acids and a maximum of two tryptic missed-cleavages were allowed. Results were filtered at 0.01 FDR (peptide
and protein level). Further statistical analysis was performed using Perseus (v1.5.5.2). A minimum of three LFQ valid values per group
was required for quantification. Missing valueswere imputed from the observed normal distribution of intensities. Then, a two-sample
Student’s T-Test with a permutation-based FDR was performed. Only proteins with a q-value < 0.10 and log2 ratio > 2 or < 2 were
considered as regulated.
RNA sequencing
Genomic mapping was performed by QMUL Genome Centre using Fastq files aligned to HG 19 using STAR aligner implemented in
BaseSpace (RNA-Seq Alignment pipeline v 1.1.0, Illumina). BAM file outputs from STAR were annotated using Partek Genomic Suite
(v6.6) and the RefSeq data base (RefSeq 21). Differential analysis was performed with Partek Genomic Suite (v6.6) running ANOVA.
Statistical analyses
Statistical analysis was performed using Student’s t test except were specified. P values represent the following: * p < 0.05;
** p < 0.01; *** p < 0.001
DATA AND CODE AVAILABILITY
Gene Ontology Analysis
Gene Ontology Analysis was performed using STRING: functional protein association networks (https://string-db.org/) for the
proteomic dataset. For the RNA seq datasets a combination of DAVID Functional Annotation Bioinformatics Microarray Analysis
(https://david.ncifcrf.gov/) and PANTHER - Gene List Analysis (http://www.pantherdb.org/) was used. Gene Set Enrichment Analysis
(GSEA) was performed using the GSEA software (Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard
(https://www.broadinstitute.org/gsea)).
Repository Information and Accession Numbers
The accession number for the sequencing data reported in this paper is GEO: GSE131503.
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repos-
itory with the dataset identifier PXD: 010379.Cell Reports 27, 3956–3971.e1–e6, June 25, 2019 e6
